30 April 2020
Safety Updates on Health Products & Devices
Reference: CIR-2019-00000155
To all health facilities / all health care practitioners in Dubai's private health sector:
Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated
- Safety update of a pharmaceutical product Actemra / RoActemra (Tocikizumab)
- Safety update of a pharmaceutical product Benlysta (Belimumab)
- Alerts on the use of E- Cigarette
- Warning from using herbal product Lotus Flower Capsule
- Warning from using herbal product Magnum XXL Capsule
- Warning from using herbal product X Power 3 Tablet
- Safety alert for the medical device Automatic Transport Ventilators
- Removal of Suspension of registration import & marketing of Amoclan Suspension
- Suspend importation & recall of pharmaceutical product Phenylephrine 10mg
- Recall all batches & Suspend importation of Quinine Dihydrochloride 300mg/2ml inj
Thanks in advance for your good co-operation
Drug Control Section
Health Regulation Sector
DHA
Supporting Documents:
إضافة تحذير على المستحضر الدوائي Actemra RoActemra (Tocikizumab.pdf:
View Document
إضافة تحذير على المستحضر الدوائي Benlysta (Belimumab).pdf:
View Document
Circular - 1.pdf:
View Document
تحذير من استخدام مستحضر عشبي Lotus Flower Capsule.pdf:
View Document
تحذير من استخدام مستحضر عشبي Magnum XXL Capsule.pdf:
View Document
تحذير من استخدام مستحضر عشبي X Power 3 Tablet.pdf:
View Document
تقرير سلامة للوسيلة الطبية Automatic Transport Ventilators.pdf:
View Document
Amoclan Suspension.pdf:
View Document
Phenylephrine 10mg.pdf:
View Document
Quinine Dihydrochloride 300mg2ml inj.pdf:
View Document
